SEC Filing Summary
Filed entity: Aeglea BioTherapeutics, Inc. The request identifies Spyre Therapeutics, Inc., but the supplied Form 10-Q is for Aeglea BioTherapeutics, Inc. for the quarter ended September 30, 2019. The financial statements are unaudited and cover the three and nine months ended September 30, 2019, with comparable 2018 periods.
Business Context and Reporting Period
Aeglea was a clinical-stage biotechnology company engineering human enzymes for diseases with unmet medical needs. Its lead candidate, pegzilarginase, was being evaluated in a global pivotal Phase 3 trial for Arginase 1 Deficiency and in a Phase 2 open-label extension study. The company was also advancing AEB4104 for homocystinuria and AEB5100 for cystinuria.
The company had no approved products and had not generated product revenue. Its sole historical revenue source was a CPRIT research grant, which ended in May 2018.
Financial Performance and Position
| Metric | Q3 2019 | Q3 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Research and development expense | $17.8 million | $8.9 million | +100% |
| General and administrative expense | $4.3 million | $3.3 million | +30% |
| Net loss | $21.6 million | $11.9 million | +81% |
| Net loss per share | $0.66 | $0.54 | Higher loss per share |
| Metric | Nine months 2019 | Nine months 2018 | Change |
|---|---|---|---|
| Grant revenue | $0 | $3.9 million | Down $3.9 million |
| Research and development expense | $47.0 million | $24.9 million | +89% |
| General and administrative expense | $11.4 million | $9.1 million | +25% |
| Net loss | $56.8 million | $29.5 million | +93% |
| Net cash used in operating activities | $49.4 million | $25.0 million | Higher cash burn |
- At September 30, 2019, cash and cash equivalents were $24.5 million, marketable securities were $64.2 million, and restricted cash was $1.5 million, totaling $90.2 million of cash, cash equivalents, marketable securities and restricted cash.
- Working capital was $77.2 million and accumulated deficit was $173.6 million.
- The company reported no debt or credit facility. Total liabilities were $20.3 million, including $5.2 million of lease liabilities.
- Financing activities provided $65.0 million during the first nine months, primarily from the February 2019 public offering, which generated $64.5 million of net proceeds.
- Net cash used in investing activities was $12.1 million, principally reflecting purchases of marketable securities.
- Interest income increased to $1.7 million from $0.7 million for the comparable nine-month period, reflecting higher invested balances.
Material Changes Versus the Prior Comparable Period
- R&D spending increased substantially as the company invested in pegzilarginase manufacturing and pre-commercial activities, initiated the Phase 3 PEACE trial, advanced homocystinuria toxicology and IND-enabling work, and expanded clinical and manufacturing personnel.
- Q3 manufacturing expense increased by $6.0 million, nonclinical expense by $1.4 million, clinical development expense by $0.9 million, and personnel-related expense by $0.6 million.
- For the first nine months, higher R&D expense included $12.5 million of additional manufacturing expense, $6.0 million of additional clinical development expense, $2.5 million of additional personnel expense, and $1.1 million of additional nonclinical expense.
- The CPRIT grant no longer contributed revenue; the full $19.8 million grant had been recognized over its term through May 2018.
- The company adopted ASC Topic 842 lease accounting on January 1, 2019, recognizing operating lease right-of-use assets and lease liabilities. It also entered into a new headquarters and laboratory lease in Austin, Texas, running through April 2028.
- Shares outstanding increased materially following the February 2019 offering and issuance of pre-funded warrants. None of the pre-funded warrants had been exercised as of September 30, 2019.
Guidance, Outlook, Commentary and Risks
- Management expected to continue generating operating losses and anticipated that expenses would increase as clinical development, manufacturing, pipeline programs, intellectual property protection and public-company activities expanded.
- Based on its operating plans, management believed existing cash, cash equivalents and marketable securities were sufficient to fund operations through the first quarter of 2021. The filing states that additional financing would be required to complete all planned research and development activities.
- Topline data from the Phase 3 PEACE trial was expected in the first quarter of 2021. Management also expected to file an IND or CTA for AEB4104 in the first quarter of 2020 and for AEB5100 in the second half of 2020.
- In July 2019, the FDA granted Breakthrough Therapy Designation to pegzilarginase for Arginase 1 Deficiency. The company also reported Fast Track, orphan drug and Rare Pediatric Disease designations, but emphasized that these designations do not assure approval or commercial success.
- September 2019 data from 14 patients after 20 doses of pegzilarginase showed sustained plasma arginine reductions, 11 of 14 clinical responders based on mobility assessments, and generally favorable tolerability. Reported serious adverse events included hypersensitivity and hyperammonemia.
- The company concluded enrollment in its pegzilarginase and pembrolizumab trial in small cell lung cancer and was exploring a partnership for further oncology development.
- Key risks included clinical-trial failure or delay, enrollment limitations in rare diseases, safety or immunogenicity concerns, manufacturing and supply constraints, regulatory uncertainty, dependence on third parties, intellectual-property challenges, competition, reimbursement uncertainty and the need for additional capital.
- The company had no material pending legal proceedings and stated that its disclosure controls and procedures were effective at the reasonable-assurance level.
Most Important Facts to Verify
- Confirm the correct issuer: the supplied filing is Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Verify the company’s cash runway assumptions and whether subsequent spending, clinical results or financing activity changed the projected funding date.
- Review Phase 3 PEACE enrollment, topline results and regulatory interactions, including the adequacy of clinical endpoints and treatment duration.
- Assess whether pegzilarginase safety, hypersensitivity, hyperammonemia or immunogenicity findings could affect development or approval.
- Track manufacturing capacity, cost escalation and third-party supply arrangements for pegzilarginase and pipeline candidates.
- Evaluate potential dilution from the $200 million shelf registration, the $60 million at-the-market facility and the 4 million outstanding pre-funded warrants.
- Review the University of Texas license for milestone, royalty, sublicense-revenue-sharing and termination provisions.